Suppr超能文献

循证医学最新进展在原发性胆汁性胆管炎中的应用。

Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis.

机构信息

Liver Institute Northwest, Seattle, Washington, USA.

UC Davis Health, Sacramento, California, USA.

出版信息

Am J Gastroenterol. 2023 Feb 1;118(2):232-242. doi: 10.14309/ajg.0000000000002070. Epub 2022 Sep 21.

Abstract

Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune liver disease that can progress to end-stage liver disease and its complications. A previous expert review panel collaborated on a consensus document for gastroenterologists and other healthcare professionals regarding the care of patients with PBC. Subsequently, there have been several recent important developments in the diagnosis, treatment, and monitoring of patients with PBC. These include updates to prognostic models on risk stratification, new noninvasive tools for staging of disease, updates to the appropriate use of and long-term treatment results with obeticholic acid as a second-line treatment, the emerging therapeutic role of fibrates, and the advancement of investigational agents for managing PBC. In this updated expert consensus document, we provide updates on staging, the use of noninvasive prognostic tools, and a treatment algorithm to provide evidence-based and practical tools for clinicians who manage PBC, with the ultimate goal to improve the long-term outcomes for patients with this chronic liver disease.

摘要

原发性胆汁性胆管炎(PBC)是一种慢性、胆汁淤积性、自身免疫性肝病,可进展为终末期肝病及其并发症。一个先前的专家审查小组合作制定了一份共识文件,供胃肠病学家和其他医疗保健专业人员参考,以了解 PBC 患者的护理。此后,在 PBC 患者的诊断、治疗和监测方面有了几项近期的重要进展。这些进展包括对风险分层的预后模型进行更新,用于疾病分期的新无创工具,更新了作为二线治疗的奥贝胆酸的合理使用和长期治疗结果,纤维酸类药物治疗作用的出现,以及用于管理 PBC 的研究性药物的进展。在这份更新的专家共识文件中,我们提供了分期、无创预后工具使用以及治疗算法的最新信息,为管理 PBC 的临床医生提供基于证据和实用的工具,最终目标是改善患有这种慢性肝病患者的长期预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e1/9889200/7cf283dde103/acg-118-232-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验